Pharmaceuticals, Biotechnology and Life Sciences
Avacta said that Affimer reagents recently generated for development of a point-of-care COVID-19 antigen saliva test have now also been shown to block the interaction between the virus’ spike protein and ACE2, a receptor on human cells that is key to the virus infection pathway.
Avacta Group said on Monday that the first major immunogenicity study of Affimer technology using human ex-vivo samples was successful with a range of Affimer proteins shown to have low immunogenicity comparable with the marketed antibody Avastin.
Avacta expects to license Affimer technology in 2017, and it says this year is very optimistic for its shareholders.
Professor Gerard Evan, FRS, has joined Scientific Advisory Board of Avacta Group, the developer of Affimer biotherapeutics and research reagents.
Avacta Group will present detailed data from the first pre-clinical in-vivo studies of its therapeutic Affimer platform